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Adenocarcinoma of the prostate gland is a leading cause of
death among men in the USA and UK. It has a rising inci-
dence of morbidity and mortality in the Asian and Eastern
European countries, approximately one in six men will be
diagnosed as having prostate cancer during their lifetime
[1e4]. Conventional diagnostic techniques for the diagnosis
of prostate cancer are serum prostate-specific antigenclare no conflicts of interest.
. Egitim ve Aras‚tırma Hasta-
kara 06110, Turkey.
tmail.com (H. Aydın).
5.01.002
ng Medical University. Published b(PSA), digital rectal examination, and transrectal
ultrasound-guided biopsy (TRUS); in men with an elevated
PSA level, definitive diagnosis of prostate cancer requires
histologic sampling that is obtained invasively at biopsy or
surgery [1,2,4e6]. However, standard sextant biopsy ob-
tained by TRUS has lower sensitivity and specificity to
delineate the malignant foci, has considerable false-
negative rates up to 40% even with whole-mount histopa-
thology, high false-positive rates due to prostatitis, hem-
orrhage, hyperplastic nodules, and post-treatment sequela
and, meanwhile, causes an increased number of unnec-
essary random prostate biopsies which can miss significant
disease and index lesions [4e10]. Its utility in the local
staging of prostate cancer is also limited because of the
failure to show seminal vesicle invasion and extracapsulary Elsevier Taiwan LLC. All rights reserved.
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[2,6,11]. Magnetic resonance imaging (MRI) provides in-
cremental value to biopsy and rectal examination for can-
cer depiction, provides excellent anatomic screening of
prostate gland due to its high tissue contrast resolution
compared to other imaging techniques, and can aid in the
cancer management, from initial diagnosis to treatment
planning and follow-up of patients, and is also helpful in the
assessment of extraprostatic extension of the tumor
[1,2,4e6,12e15]. Application of 3 T high field magnets and
integrated endorectal surface coil with pelvic phased-array
coil has improved the outcomes by resulting in higher signal
to noise ratios (SNR) which can led to accurate localization
of prostatic tumor foci [2,4,6,11,14,16]. The current MRI
protocol consists of anatomic sequence sets, T1-and T2-
weighted imaging (T1W, T2W), and functional techniques
that include diffusion-weighted imaging (DWI) and
apparent diffusion coefficient (ADC) mapping, dynamic-
contrast enhanced imaging (DCE-MRI), and proton-MR-
spectroscopy (H-MRS) [1,2,4,5,11e15].
Anatomic MRI sequences
T1W
Precontrast T1Waxial images of themale pelvis canbe added
to the routine MRI protocol to detect postbiopsy glandular
hemorrhage, benign prostate hyperplasia (BPH), prostatitis,
etc. to improve the accuracy of themultiparametric (MP) MR
approach, especially DCE-MRI, as biopsy-related hemor-
rhagemay interfere the diagnostic capability of this high MRI
technique, can also mimic tumors on T2W [1,2,6,17e19]. To
our knowledge and with regard to relevant literature, the
time interval between biopsy and MRI should be> 4 weeks in
order to decrease the influence of postbiopsy hemorrhage on
staging of prostate tumors and to prevent TRUS biopsy-
related hemorrhage, interfering with MRI of the prostate
[2,4,6,15,19]. The interpreting criterion of T1W for depicting
prostatic cancer is the low-intensity area relative to high-
intensity fatty tissue of normal prostate zones [6,17,19 ].
T1W has limited value in the diagnosis as the delineation of
the tumor foci from normal zonal gland anatomy is difficult
and requires more experience (Fig. 1).
T2W
T2W sequence is the most widely used MRI sequence
because zonal prostate anatomy, prostatic capsule, neu-
rovascular bundles, and seminal vesicles are best observed
in this technique. The prostatic capsule appears as a thin
low intensity rim circumscribing the peripheral zone (PZ)
and seminal vesicles present high signal due their high fluid
content [1,2,11,20]. The criterion for cancer presence in
T2W is a low-signal intensity mass or nodule with ill-defined
margins in the PZ without hyperintense signal on unen-
hanced T1W [2,6,11e13]. However, some prostate tumors
are isointense and some benign conditions such as hemor-
rhage, fibrosis, atrophy, prostatitis, prostate hyperplasia,
and changes after hormonal and radiation therapy,
may cause T2 signal loss in the PZ so use of T2W alone
may predict limited sensitivity and lower specificity[2,6,11,16,17,21]. Small sized tumors (<5 mm), especially
within the central gland and transitional zone (TZ), can
easily be misdiagnosed by routine anatomic T1eT2W se-
quences as there is a significant overlap between tumors
and benign hyperplastic nodules in these zones
[1,2,6,16,18]. Central gland and TZ tumors mostly generate
homogeneous, ill-margined hypointense lesion on T2W
without a distinct capsule [22,23]. ECE and seminal vesicle
invasion are of importance for T2W to detect and stratify,
criteria for detecting ECE on T2W include at least one of the
following: disruption of prostatic capsule; obliteration of
rectoprostatic angle; invasion of periprostatic fat; irregular
capsular bulge; and retraction, asymmetry, or involvement
of the neurovascular bundles [2,11,24]. Reported sensitivity
and specificity of T2W for cancer detection has ranged
between 30% and 95%, reported sensitivity of T2W for ECE
and local staging is in the range of 30e80% and specificity is
in the range of 45e98% [1,2,4,6,11,25e29]. In our experi-
ence, these wide sensitivity and specificity ranges may be
due to the coil style used, magnet strength and software
technology, quality of the imaged patients, size of the
tumor and its ECE or seminal vesicle infiltration, experience
level of observers, and reference histopathology
[1,2,4,5,24] (Figs. 1, 2, 3).
Functional sequences
DWI and ADC mapping
DWI, which assesses the Brownian motion of free water
within intra- and extracellular spaces, is initially used in the
detection of acute cerebral stroke and then recently has
become available for the detection of abdominal and pelvic
tumors, thyroid nodules, etc. [1,2,30e32]. Normal prostate
tissue is rich in glandular tissue, which has higher water
diffusion rates, mostly depicted on ADC mapping, which
allows quantitative analysis of DWI by measuring the degree
of diffusion [2,5,11,33e36]. Prostate cancer shows
restricted diffusion with high signal on DWI and low signal
on ADC maps which is due to increased cellularity of ma-
lignant lesions with reduction of extracellular space and
restricted motion or diffusional displacement of water
molecules into the intracellular space so DWI provides the
differentiation of benign from malignant prostate tissue
and ADC values are significantly lower in tumors than in
normal prostate [2,11,33,34,37e39]. Three-Tesla scanners
with higher b-values (often 1000 s/mm2) and parallel im-
aging techniques in contrast to 1.5 T MRI, provide many
advantages via increasing SNR and spatial resolutions,
faster acquisition times, and decreasing susceptibility ar-
tefacts by using an endorectal coil [2,6,16,26,33,34,36,40].
The diagnostic criterion for DWI in the detection of prostate
cancer is the focal or conglomerated areas, which are
hyperintense in DWI and hypointense in ADC mapping,
relative to the surrounding prostate tissue
[2,6,11,20,33e36,39]. In contrast to other methods, DWI
has the advantage of not requiring intravenous contrast
material and of being simple to process without any addi-
tional software, it also requires less time to perform and is
easy to interpret for the readers. A limitation of DWI is that
the echo-planar imaging pulse sequence is mostly used to
Figure 1. Consecutive (A, B) T2-weighted and (C, D) T1-weighted images show hypointensity in both peripheral regions in a
patient with prostate cancer.
MRI in prostate cancer 169acquire DWI and this sequence can easily be affected by
magnetic susceptibility, resulting in spatial distortion and
signal loss, which causes difficulties in the localization of
the tumor [2,6,16,20,33e36,41,42]. Parallel imaging or
alternative DWI methods based on line scan diffusion,
accumulation phases causing susceptibility artefacts, are
decreased because of a reduction in the train of gradient
echoes and sampling time; decreased scan duration with
parallel imaging also contribute to the suppression of mo-
tion artefacts [16,33,36,43]. Although 65e70% tumors
originate from the PZ, up to 30% of tumors arise from the TZ
and diagnosis of TZ cancers is difficult as benign prostate
hyperplastic nodules mostly arise from TZ
[2,11,22,23,34,44]. DWI may assist in depicting and differ-
entiating TZ prostate cancers, which can mimic cancer on
T2W by regarding nonspecific hypointense signal intensities
[22,23,34]. The addition of DWI to T2W, can improve cancer
detection in TZ, although morphological criteria described
on T2W is still the gold standard for the cancer diagnosis in
TZ and PZ [16,20e23,25,26,33,34,39]. DWI and ADC maps
have not been used to predict ECE and seminal vesicle in-
vasion of prostate cancer because of low spatial resolution,
image distortions, and artefacts. DWI findings have to be
validated for ECE and seminal vesicle infiltration especially
by DCE-MRI [2,11,17,24e26,45]. Diffusion tensor imaging is
a new technique that is mostly related with the fractional
anisotropic diffusion of water molecules, may be used for
investigating and differentiating normal prostate tissue and
cancer at higher field strengths by measuring fractional
anisotropy coefficients of tissues, and may show the spread
of cancer beyond prostatic capsule by fiber tracking in the
prostate gland [46] (Figs. 2, 3).DWI consists of Gaussian diffusion, simple linear function
with a monoexponential decay which is significant at low b-
values and non-Gaussian diffusion, a quadratic functional
logarithm which is significant in higher b-values, > 750 s/
mm2 [47e49]. At high b-values, molecular diffusion differs
from random conventional diffusion because of the located
barriers within cellular environments which leads to sig-
nificant variations from simple linear monoexponential
Gaussian diffusion to quadratic non-Gaussian diffusion, well
contributed and appreciated for prostate [48,50e52].
However, at low b-values and insufficient SNR, non-
Gaussian diffusion and non-Gaussian noise on the real
measured diffusion signals could not be differentiated
[47,48]. Intravoxel incoherent motion (IVIM)-DWI,
described initially by Le Bihan et al [53], utilizes low b-
values in order to influence diffusion of water molecules
within the capillary bed. According to the IVIM-DWI model,
blood microcirculation within the capillaries (Perfusion)
and molecular diffusion can be differentiated by using a
biexponential decay model, assuming one pseudo-diffusion
and one molecular diffusion so perfusion effects and pure
diffusion in DWI can be separated [47,48,53,54].
Within this biexponential model, decay curves were
equated as follows:
SðbÞ : So½ð1 fÞ:expð  bDÞ þ f:exp½  bðDþD)Þ ð1Þ
where S(b) is the measured diffusion signal, So is the signal
intensitywithout diffusion, b is the b-value, f is the perfusion
fraction, D is the diffusion coefficient, slow component, and
D* is the perfusion-related diffusion coefficient, fast
component [47,48,50,54,55]. In previous research, it was
found that: D and ADC were significantly decreased in
Figure 2. (A) T2-weighted and (B) T1-weighted images show hypointensity in both peripheral regions and indeterminate
hypointensity in the left transition zone. By contrast, (C) diffusion-weighted imaging and (D) apparent diffusion coefficient
mapping of the same patient reveals diffusion restriction not only in both peripheral zones but also left and right transitional zones
(parallel to biopsy results of this patient).
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sue, fwas lower in tumors than normal benign prostate tissue
when high b-values were used, which contradicts the the-
ories about the angiogenesis within the tumor could prob-
ably be observed on DCE-MRI, was significantly increased
with b-values below >750 s/mm2, D* was almost indistin-
guishable between tumors and benign prostate tissues or
BPH [18,47e50,54]. Regardless of the derived b-value, small
tumors (5 mm), especially within the center of the gland
and TZ, as well as unenhanced and hypoperfused tumors
mostly located in the central gland and anterior fibromus-
cular stroma, could easily be misdiagnosed by IVIM and f
measurements as these approaches are more helpful and
contribute more on the most perfused organs, such as thy-
roid, kidney, and liver, DCE-MRI should be added to diffusion
and perfusion analysis for those small-sized suspicious cen-
tral gland tumors [6,17,18,49,51,52]. Perfusion measure-
ments were performed without requiring an intravenous
contrast material injection, which is relevant in patients
with chronic renal failure or severe allergic reactions to
gadolinium-based contrast materials [47].
IVIM measurements can be performed on 3.0 T scanners
with endorectal coil application, and choice of b-value
mostly reinforces the diffusioneperfusion models there-
fore, an appropriate range of b-values used in prostate
studies or contribution of Gaussian and non-Gaussian
diffusion modeling predict appreciable data for the diag-
nosis of prostate cancer and IVIM measurements can be
incorporated to MP-MRI paradigm or within DWI sections to
detect prostatic tumor [47,48,50,54]. Susceptibility arte-
facts and bulky patient movement mostly caused by
discomfort due to endorectal coil application, may degrade
and distort the quality of DWI so use of pelvic phased arraycoil under those circumstances could differentiate malig-
nancy from benign tissues in PZ [6,16,34] (Fig. 3).
An alternative approach to the biexponential model is
the stretched exponential model using Kohlrausch decay
constant (Dk) and a as quantitative parameters. This is:
mostly reliable at high b-values (>650 s/mm2); more
robust than the biexponential model at higher noise and
insufficient SNR; may serve as applicable quantitative
tools for the detection of tumor; and DK is decreased in
prostate tumors and a value is elevated in cancer when
compared with normal-appearing prostate tissue [55].
Stretched modeling is a new entity: reliability and
reproducibility of this approach has to be validated in
forthcoming studies.DCE-MRI
DCE-MRI has emerged as an imaging biomarker for diag-
nosing prostate cancer. It depicts the vascularity, blood
flow, and vascular permeability of tissues. Prostatic tumors
show early-rapid enhancement and early wash out on this
functional MR sequence but it has some shortcomings such
as some smaller and low-grade lesions may not enhance and
several benign conditions such as prostatitis, BPH, and
hemorrhage after biopsy may enhance, which may give rise
to high false-negative and false-positive rates
[1,2,6,11,17,56]. Within the central gland, distinguishing
between tumor foci and hyperplastic nodules are relatively
challenging, BPH nodules also rapidly enhance but usually
wash out slowly [2,17,56,57]. However, prostatic tumors
show early, rapid enhancement, and early fast wash out
due to the presence of highly permeable neoangiogenic
Figure 3. Another patient with (A) axial T2-weighted and (B) coronal T2-weighted images indicating cancer foci in left peripheral
region. (C) Diffusion-weighted imaging and (D) apparent diffusion coefficient mapping depict diffusion restriction in this region. In
addition, T2-weighted, diffusion-weighted imaging, and apparent diffusion coefficient mapping revealed neurovascular bundle
invasion in these images.
MRI in prostate cancer 171vessels [1,2,6,17,56]. This angiogenesis consists of newborn
blood vessels, supplying the growth of tumor, meanwhile
the vascular neoendothelium itself also plays a role in the
stimulation of tumor cells by several angiogenic factors and
matrix proteins such as vascular endothelial growth factor,
matrix metalloproteinases, fibroblast growth factor 2,
cyclooxygenase 2, and transforming growth factor b
[17,56,58]. Microvessel density is another quantified entity
for neovascularity, higher in prostate cancer areas than in
benign prostate tissue and also significantly higher in
metastasizing prostate cancer, in those of higher Gleason
grades [17,56]. Basic principles of DCE-MRI are mainly
based on changes at three compartments: intracellular
space, extravascular extracellular space (EES), and the
microvasculature due to alteration of blood flow, micro-
vascular permeability and microvascular surface area
[1,11,17,56]. Dynamics of the contrast motion into and out
of the EES can be quantified by using pharmacokinetic
analysis which has four principal parameters to describe
this dynamic process: Ktrans (transendothelial transport of
contrast medium from vascular compartment to tumor
interstitium) known as transfer constant, Ve (volume of EES
per unit volume of tissue, also named as interstitial space
or leakage space), Vp (fraction of plasma per unit volume of
tissue), and kep (reverse transport of contrast agent from
extracellular space to plasma, named as rate constant)
[1,11,17,18,56]. DCE-MRI techniques are typically per-
formed by two-dimensional (2D) or 3D-T1W gradient echo
sequences with shorter echo acquisition after bolus appli-
cation of intravenous contrast agent, which supplies high
SNR, high sensitivity to T1 changes, rapid data acquisition,
and detailed anatomic knowledge. The acquisitions can beobtained approximately every 5e10 seconds to detect the
early tumoral enhancement; longer acquisitions are not
recommended as they can’t easily visualize the early
enhancement [1,4,6,17,18,56,59]. DCE-MRI can be
analyzed by quantitative, semiquantitative, or qualitative
approaches; the most widely used one, the quantitative
approach, is based on pharmacokinetic modeling of gado-
linium concentration changes by determining Ktrans, kep, Ve-
like permeability parameters. Prostate tumors generally
have higher quantitative values, but BPH or prostatitis
mostly arising from central gland may show overlapping
permeability values when compared to those values of tu-
mors [1,11,17,56] (Fig. 4).
The semiquantitative approach is based upon intense
tissue or glandular enhancement plus wash out without
reference to pharmacokinetic model, parameters of this
technique include onset time of contrast uptake, time to
peak, maximum signal intensity, peak enhancement, and
wash-in and wash-out gradient curves [17,56]. Three main
dynamic curves have been obtained after initial gadolinium
uptake: Type 1, persistent increase; Type 2, plateau; and
Type 3, decline and wash out of contrast agent after first-
pass. Type 3 is believed to be the most suspicious for pros-
tate tumor but, type 1 and 2 curves can also be found in
prostate cancer [17,56,59,60]. Semiquantitative methods
are very simple to performand do not reveal the quantitative
approaches but susceptible to variations of repetition time,
echo time, flip angle, and gain factors, and also assess the
concentration of contrast agent not only in the tumor but all
over the region as well [17,56,60]. Qualitative or visual
analysis is based on the general consideration of leaky tu-
moral vessels that show early rapid enhancement after
Figure 4. (A) T2-weighted and (BeD) consecutive dynamic-contrast enhanced magnetic resonance images of a patient with
prostate cancer. T2-weighted image indicates heterogeneous hypointense areas in both peripheral, transitional, and central zones
but dynamic-contrast enhanced magnetic resonance images show contrast enhancement in both peripheral regions only.
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between capillaries and tumor cells, early arterial
enhancement is the predictor of malignancy but some
benign conditions such as BPH and hemorrhage may show
rapid enhancement, overshadowing qualitative analysis and
limiting the safety of qualitative DCE-MRI technique
[6,17,56e58,60]. The criterion for DCE T1W for the detec-
tion of cancer and ECE is the presence of asymmetric high
contrast enhancement, especially early nodular enhance-
ment (before the enhancement of the rest of the prostatic
fossa and pelvic muscles). The presence of early contrast
wash out and short initial uptake or increased time to peak of
contrast agent, and combination of peak enhancement with
gadolinium wash out, suggest the invasion of seminal vesi-
cles [2,5,6,11,17,24,56]. The limitations of DCE-MRI are
rectal peristalsis and patients movement mostly due to
discomfort, which is caused by the endorectal coil applica-
tion. These may lead to noisy curves and distorted low
quality dynamic images. Bowel preparation by rectal enema
1e3 hours before MRI, glucagon-like antiperistaltic agent
use, and 4e6 hours fasting can be recommended to over-
come these disabilities [17,18,56,60]. Small unenhanced
tumors, within the central gland and TZ can easily be mis-
diagnosed and enhancement of benign conditions, such as
prostatitis, post-biopsy hemorrhage, glandular hyperplasia,
BPH, and fibrosis, may cause elevated false-positive and
false-negative rates of DCE-MRI [6,17,18,22e24,44,56,57].
AnMR scanner of Grade 3.0 Tmay cause some problems for
DCE-MRI due to gradient-echo imaging; lower specific ab-
sorption rate (SAR), strong susceptibility artefacts, larger
chemical shift, higher sensitivity to field inhomogeneities,
and higher gain in SNR for T2W rather than T1W sequencesare the main disadvantages of gradient echoes, which are
more visible in 3.0 T systems [17,18,40,56,60]. Thin slice
use without gap, 3D acquisition, and small field of view
application can overcome the weakness of gradient-echo
sequences used in DCE-MRI and provide high sensitivity to
T1 shortening in the EES, high SNR, and rapid acquisition in
3.0-T scanners [17,18,40,60].H-MRS
H-MRS provides information about the metabolite concen-
trations within a voxel of the prostate gland to show the
aggressiveness of the cancer and to improve the tumor
localization and volume estimation with MRI
[1e3,7,11,29,61]. H-MRS has a great importance in the
detection of cancer, ECE and local staging of prostate tu-
mors by locating the peaks of chemical compounds. A sig-
nificant reduction of citrate (Cit), elevation of choline
(Cho), and increased Cho/Cit and Cho þ Cre/Cit ratios have
been documented for the diagnosis of prostatic adenocar-
cinoma in 3D-HMRS, compared with the benign prostate
tissue and BPH and Cho/Cit ratio can be used as predictor of
malignancy [2,3,6,11,28,29,59,61]. Normal PZ contains low
Cho level and high levels of Cit whereas prostate cancers
have high Cho level and low levels of Cit, and normal
secretory epithelial cells within the prostate gland have
excess zinc, which inhibits the citrate-oxidizing enzyme,
aconitase, leading to the accumulation of Cit.
[2,3,7,28,29]. Cancer cells have lower zinc levels, causing
an increase in the aconitase activity and decreased Cit level
due to the oxidation; increased Cho level in tumors is due to
MRI in prostate cancer 173the increased cell turnover, resulting to increased levels of
free Cho compounds [2,7,27,61]. Additional metabolites
(e.g., polyamines and spermine) detected in the prostate
by high-resolution 2D spectroscopy ex vivo and single voxel
J-resolved in vivo, can eventually improve the diagnostic
accuracy of H-MRS [2,6,62,63], however polyamine peaks
can be detected at very high field strengths. H-MRS has
been shown to facilitate sensitivities and specificities
ranging 65e92% and 49e80% for tumor detection and ECE,
respectively [2,3,6,11,27e29,59,61,64,65]. Higher sensi-
tivity and comparatively lower specificity of H-MRS in the
detection and staging of prostate cancer can be explained
by partial volume effects and strong signals from sur-
rounding tissues, mainly seminal vesicles, BPH, and pros-
tatitis. Spectral degradation and metabolite SNR variations
between voxels in the same patient as MRI can be per-
formed up to 4e8 weeks after a prostate biopsy and also TZ
tumors may show substantial overlapping of metabolites
between BPH and prostate cancer [4,6,11,22,23,64e66]. H-
MRS use in conjunction with MRI can improve ECE and
overall staging of prostate cancer, but as MRS resolution is
lower than conventional MRI, H-MRS may not detect small
extracapsular spreading tumor and therefore cannot play a
significant role in the assessment of seminal vesicle invasion
but future use of 3D-spectroscopic approaches with smaller
voxels can permit the detection of smaller tumors
[11,59,61,65,67,68]. The addition of DWI to H-MRS data can
significantly improve specificity up to 90% [41,42,64]. H-MRS
has some disadvantages such as long acquisition and post-
processing times, requiring homogeneous shimming and
advanced operating skills to achieve high quality data,
needing expertise staff and specialized high field MR sys-
tems. With advanced software technology, analyzing and
interpreting H-MRS data are not difficult and more reliable
in the diagnosis of prostate cancer. An H-MRS scan of about
6 minutes with long echo time acquisition is not a long time
for a patient to stay inside the MR unit [1e6,27e29,61]
(Figs. 5, 6).
H-MRS can be performed using an endorectal coil as
multivoxel approach with point-resolved spectroscopy
voxel excitation by band-selective inversion with gradient
dephasing, waterelipid suppression and spatial encoding by
3D-chemical shift imaging with high resolution at all three
dimensions via 3D-echo time: 135e170 ms acquisition and
spectral and/or spatial pulses optimized for quantitative
detection of Cho and Cit. [3,5,6,29,42,61,65,68e70]. With
the application of a Hamming filter; Effective standard
voxel size of 1 cm  1 cm  1.5 cm can be obtained, then
magnetic field homogeneity is optimized by using both
automated and manual shimming, phase encoding will be
applied to produce 3D-MR spectroscopic arrays of proton
spectra throughout the prostate [3,6,28,29,61,68,69].
After postprocessing of the time-domain by zero filling
to 1024 points, multiplication by Hanning filter, Fourier
transformation, and phase-baseline correction, spectral
data can be analyzed to provide standard deviation and
peak estimates of Cho, Cit, and creatine (Cre) resonances,
Cit resonance is found at 2.6 ppm, Cre at 3.0 ppm, and Cho
resonance at 3.2 ppm. For further analysis, Cho/Cit and
Cho þ Cre/Cit ratios are used for the tumor depiction and
tumor aggressiveness, correlated with the Gleason score
[3e7,27e29,41,42,61,65,71,72].Clinical experience with MP-MRI
Most of the urologists in our department refer the patients
with elevated PSA levels to MRI after TRUS biopsy-based
diagnosis and most of the prostate MRI is performed
retrospectively; they rely more on biopsy-based definite
diagnosis prior to MRI but to our belief, in case of
the presence of ECE of tumor and the presence of small
tumors especially located in the central TZ and in
the probable operable patients without any distant
metastasis, MP-MRI can be performed before TRUS-biopsy
to screen for prostate cancer. Among those circumstances,
surgical results are the gold diagnostic standard and one
can easily skip TRUS-biopsy prior to surgery [2,4,5,16,22].
Among the existing imaging approaches, MRI is the best
modality for depicting prostate cancer foci, but it is clear that
no single MRI sequence is sufficient to detect cancer alone.
Each sequence has its own advantages and shortcomings but
the MP-MRI approach leads to a high diagnostic profile in the
detection of prostate cancer [1,4e6,11e13,15,17,26].
Application of these high-MR techniques and the combined
use of them cause an increased diagnostic rate in the
screening and staging of cancer, TRUS-biopsy, and/or use of
one MR sequence, such as T2W, alone can miss the tumor but
MP-MRI, especially the combined use of DWI-DCE MR and H-
MRS, overcome this limitations and show the tumor with
higher sensitivity and specificity profiles, up to 90e95%
[1,2,4e6,11,12,26].
Recently, MP-MRI has been shown to improve the diag-
nostic accuracy of detecting prostate cancer, and also has
been reported in the prediction of aggressiveness of the
cancer, which is based on PSA levels and Gleason scores in
the previous decades [1,2,4,5,7,12,13,15]. With regard to
previous reports about MP-MRI, involving three or more se-
quences, Tamada et al [26] predicted 83% sensitivity by
combining T2W with DWI and DCE-MRI in the diagnosis of
prostate cancer whereas DCE-MRI alone has shown 43%
sensitivity. Turkbey et al [5] reported that four-sequence MP
approach (T2W, DCE-MRI, DWI, and H-MRS) had 86% sensi-
tivity and almost 100% specificity, and MP-MRI has beenmore
accurate in PZ tumors than those in central gland. Delong-
champs et al [12] revealed that the three-sequence MP
approach (T2W, DWI, and DCE-MRI) had a significantly higher
performance for cancer detection in PZ but failed to improve
performance in TZ. Aydin et al [6] predicted 91% sensitivity
and 24% specificity for the detection of cancer by the com-
bined use of five sequences (T1W, T2W,DWI, DCE-MRI, andH-
MRS), and recommended the use of pelvic-phased array coil
and endorectal coil together to improve the specificity and
overcome the high false-negative rate (Fig. 6).
Turkbey et al [4] reported 73% sensitivity and 89%
specificity for detecting PZ and TZ prostate cancers by
using three-sequences, T2W, DCE-MRI, H-MRS. Fu¨tterer
et al [59] revealed 68e91% sensitivity and 74e96% speci-
ficity in the depiction of PZ and central gland tumors with
three-sequence multiparametric approach (T2W-DCE-MRI,
H-MRS). With regard to these previous reports, urologists
can rely on and trust the MP-MRI yields for the surgical
treatment planning and patient care, and do radical
prostatectomy to the prostate cancer patients more
safely.
Figure 5. (A, B) T2-weighted images of a patient show hypointensities in both peripheral regions but also multiple prostatic
nodules in the central zone. (C, D) Magnetic resonance spectroscopic evaluation of the same patient indicating high choline/citrate
ratios in left transitional zone and peripheral zone respectively.
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Figure 6. (A) T2-weighted image indicated hypointense signals in both peripheral regions suspected to be cancer foci in this
patient. (B) T1-weighted image showed hypointensity in nearly entire peripheral regions. (C) Diffusion-weighted imaging and (D)
apparent diffusion coefficient mapping showed indeterminate diffusion restriction in both peripheral regions, mostly in the right
peripheral zone. (E, F) Consecutive dynamic-contrast enhanced magnetic resonance images show contrast enhancement in both
peripheral and transitional zones. (G) Magnetic resonance spectroscopic evaluation of this patient and the spectrum indicates high
choline/citrate ratio in the left peripheral region.
MRI in prostate cancer 175MP-MRI, specifically DCE-MRI and H-MRS can also be used
to identify tumor recurrence after external-beam radiation
therapy as PSA and digital rectal examination cannot be
considered as reliable and specific entities [2,11,17,58,68].
The role of MP-MRI in prostate cancer diagnosis is not indispute and in our experience, it will be more robust and
more accurate with the advancing techniques of molecular
imaging, further multicenter trial researches, faster 3D-
acquisitions, advanced software technology, computer-
assisted diagnosis of cancer, and automated decision-
176 H. Aydın et al.supporting systems, which can enable the radiologists to
expertise about the abnormalities of the prostate gland on
MRI.
Conclusion
Recently, MP-MR approaches have evolved rapidly and are
becoming more available in clinical practice. Clinical ap-
plications of MP-MRI for detection, localization, and staging
of prostate cancer as well as the depiction of tumor
recurrence if it exists, are the main benefits of this imaging
technique. Clearly, 3-T MP-MRI with both endorectal and
pelvic phased array coil application can accurately depict
low- to high-grade prostate cancers in most cases. For the
radiologists interpreting these data precisely, it is vital to
understand the relative advantages, pitfalls, and technical
background of these morphologic and functional se-
quences. We believe that there is still a huge need for
validating prospective researches for multi-institutional
trials to improve the diagnostic rate of MP-MRI for the
detection and staging of prostate cancer.
Meanwhile, biopsies under ultrasound or MRI have to be
performed for the exact characterization and localization
of prostate lesions: blind prostate biopsies may miss many
tumors within the prostate gland, causing underestimation
of Gleason scores of tumors and their aggressiveness, MP-
MRI can guide to direct biopsies of prostate to the appro-
priate side and zone of the prostate gland, show existing
cancer, and in some cases, predict the need for repeating
biopsies. Use of MP-MRI with conjunction to conventional
prostate biopsy can definitely be performed in routine
clinical practice to further improve tumor detection and
localization, help for planning of the treatment strategies,
and improve the quality of patient care and follow-up.
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